Last deal

Amount

Seed

Stage

01.01.1993

Date

1

all rounds

Financing round

General

About Company
Millennium Pharmaceuticals is a biopharmaceutical company that develops and commercializes cancer medicines.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.1993

Operating Status

Closed (10.04.2008)

Number of employees

Company Type

For Profit

Last funding type

Seed

IPO status

Private

Description

The company, founded in 1993 and headquartered in Cambridge, Massachusetts, focuses on researching, developing, and selling cancer treatments, with a particular emphasis on VELCADE for injection. Millennium Pharmaceuticals operates globally and is a subsidiary of Takeda Pharmaceutical Co. Ltd. Additionally, the company acquired COR, a developer of pharmaceutical products for cardiovascular diseases, in 2001. Millennium Pharmaceuticals also develops compounds for viral and bacterial diseases, as well as cancer treatment.
Contacts

Contact Email

Phone number

Social url

Similar Companies
999
Atrin Pharmaceuticals

Atrin Pharmaceuticals

Atrin Pharmaceuticals is a biopharmaceutical company that is revolutionizing cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Doylestown, PA 18901, USA

total rounds

6

total raised

$1.78M

ApopLogic Pharmaceuticals

ApopLogic Pharmaceuticals develops and sells cancer treatments targeting apoptotic cell death.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Aurora, CO, USA
Actelion Pharmaceuticals

Actelion Pharmaceuticals

Actelion Ltd is a biopharmaceutical company that develops and sells low molecular weight drugs for various medical needs.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Pharmaceuticals

Location

4123 Allschwil, Switzerland

total rounds

1

total raised

$12M
Ampio Pharmaceuticals

Ampio Pharmaceuticals

Ampio Pharmaceuticals develops innovative drugs to improve patient care.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Greenwood Village, CO, USA

total rounds

3

total raised

$75.89M
M&A Details
1

Transaction name

Acquired by

Takeda

announced date

01.02.2008

price

$8.69B

Financials

Funding Rounds
1
1

Number of Funding Rounds

Their latest funding was raised on 01.01.1993. Their latest investor Venrock. Their latest round Seed

Date 
Funding Round 
Investors 
Money Raised 
Lead 
01.01.1993
1
Co-Investors
Investors
1
0

Number of lead investors

1

Number of investors

Investor 
Lead 
Round 
Partners 
No
Seed
Venrock

Venrock

Venrock partners with entrepreneurs to build disruptive, successful companies.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Venture Capital, Financial Services

Location

Palo Alto, CA, USA

count Of Investments

619

count Of Exists

216
Acquisitions
2
Acquiree Name 
Date 
Price 
Acquisition Name 
COR Therapeutics Inc acquired by Millennium Pharmaceuticals

COR Therapeutics Inc acquired by Millennium Pharmaceuticals

acquirer

Millennium Pharmaceuticals
Millennium Pharmaceuticals

date

07.12.2001

type

Acquisition

price

$1.71B
COR Therapeutics Inc

COR Therapeutics Inc

COR Therapeutics develops and markets therapeutic products for cardiovascular diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Health Care, Biotechnology, Therapeutics

Location

San Francisco, CA, USA
LeukoSite acquired by Millennium Pharmaceuticals

LeukoSite acquired by Millennium Pharmaceuticals

acquirer

Millennium Pharmaceuticals
Millennium Pharmaceuticals

date

17.10.1999

type

Acquisition

price

$635M
LeukoSite

LeukoSite

LeukoSite develops antibody treatment and care.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

Cambridge, MA, USA

total rounds

2

total raised

$12M

People

Founders
2
Raju Kucherlapati
Raju Kucherlapati

Raju Kucherlapati

Raju Kucherlapati, Ph.D. has served as a director since October 2001. He has been a professor of Medicine at Harvard Medical School since 2001 and served as scientific director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics from 2001 to 2008. Dr. Kucherlapati was a founder of Cell Genesys, Inc., Abgenix, Inc. and Millennium Pharmaceuticals, Inc. and currently serves on the board of Enlight Biosciences LLC. Dr. Kucherlapati holds a B.S. in Biology from P.R. College, Kakinada, India, an M.S. in biology from Andhra University, Waltair, India and a Ph.D. from the University of Illinois at Urbana.

current job

KEW Group
KEW Group

organization founded

4

Raju Kucherlapati

Eric Lander
Eric Lander

Eric Lander

Eric Lander, Ph.D., is a co-founder of Infinity. Lander has been a professor and associate professor of biology at the Massachusetts Institute of Technology since 1990 and a professor of systems biology at Harvard Medical School since 2004. Lander has served as the founding director of The Eli and Edythe L. Broad Institute, a biomedical research institute formed by MIT and Harvard University, since 2003 and as a member of the Whitehead Institute for Biomedical Research since 1989. From 1993-2003, Dr. Lander was the director of the Whitehead/MIT Center for Genome Research. Lander received an A.B. in mathematics from Princeton University and a D.Phil. in mathematics from Oxford University, which he attended as a Rhodes Scholar.

current job

Massachusetts Institute of Technology
Massachusetts Institute of Technology

organization founded

4

Eric Lander

Employee Profiles
144

Walid Kamoun

Associate scientific director

Tetsu Inada

Chief financial officer and vp, global vaccines

Alexandra Glucksmann

Alexandra Glucksmann

Scientist / Various roles

Tamyra A. Toole

Tamyra A. Toole

Regulatory Affairs and Quality Assurance

Barry Greene

Barry Greene

General Manager of Oncology

Anthony Coyle

Anthony Coyle

Director of Research

Eric von Hofe

Program Director

Karen Adams

Karen Adams

Assistant Controller

Activity

Recent News
1